Paradigm Shifts and Point-of-Care Decisions for Better Control of Urothelial Carcinoma/Bladder Cancer
Brought to you by:
Molecular markers can aid in the diagnosis and management of bladder cancer and support targetable treatment options. Recent approvals of targeted therapies such as adjuvant drug conjugates, fibroblast growth factor receptor inhibitors, and immune checkpoint inhibitors hold promise of improving long-term survival in patients with more advanced disease.
To learn more, join a panel of clinicians specializing in treating bladder cancer as they discuss the management of upper-tract urothelial carcinoma, non-muscle-invasive bladder cancers, and muscle-invasive bladder cancers/advanced urothelial carcinoma (UC).